Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: Subgroup analyses from the warfarin-aspirin recurrent stroke study

Ralph L Sacco, Shyam Prabhakaran, J. L P Thompson, Amy Murphy, Robert R. Sciacca, Bruce Levin, J. P. Mohr

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background and Purpose: We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort. Methods: The WARSS compared the efficacy of adjusted-dose warfarin (INR 1.4-2.8) to aspirin (325 mg/day) for recurrent ischemic stroke or death within 2 years. The effect of warfarin and aspirin was compared among prespecified and exploratory subgroups with respect to sociodemographic and vascular risk factors, stroke subtype, arterial territory, and infarct topography. Hazard ratios and 95% confidence intervals comparing warfarin to aspirin were calculated using Cox proportional hazards models. Differences in hazard ratios were tested using interaction terms. Results: No treatment differences between warfarin and aspirin were found across multiple prespecified subgroups. In a multivariate model, warfarin was associated with greater hazard among patients with moderate stroke severity (HR 1.63, 95% CI 1.005-2.64, p = 0.047) and a greater benefit among those with posterior circulation location without brainstem infarction (HR 0.54, 95% CI 0.33-0.88, p = 0.013). In post-hoc analyses of the cryptogenic subgroup, warfarin was associated with worse outcomes among patients with moderate stroke severity and better outcomes among those without baseline hypertension or with posterior circulation infarcts sparing the brainstem. Conclusions: In the WARSS, the majority of subgroup analyses showed no benefit of warfarin over aspirin. Warfarin benefit was limited to brainstem-sparing posterior circulation infarcts and select cryptogenic stroke subgroups. Pending future clinical trial evidence to the contrary, antiplatelets are recommended for survivors of noncardioembolic stroke.

Original languageEnglish
Pages (from-to)4-12
Number of pages9
JournalCerebrovascular Diseases
Volume22
Issue number1
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Warfarin
Aspirin
Stroke
Brain Stem
Brain Stem Infarctions
International Normalized Ratio
Proportional Hazards Models
Survivors
Cohort Studies
Clinical Trials
Confidence Intervals
Hypertension

Keywords

  • Anticoagulants
  • Antiplatelet therapy
  • Cryptogenic stroke
  • Recurrent stroke

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death : Subgroup analyses from the warfarin-aspirin recurrent stroke study. / Sacco, Ralph L; Prabhakaran, Shyam; Thompson, J. L P; Murphy, Amy; Sciacca, Robert R.; Levin, Bruce; Mohr, J. P.

In: Cerebrovascular Diseases, Vol. 22, No. 1, 01.06.2006, p. 4-12.

Research output: Contribution to journalArticle

Sacco, Ralph L ; Prabhakaran, Shyam ; Thompson, J. L P ; Murphy, Amy ; Sciacca, Robert R. ; Levin, Bruce ; Mohr, J. P. / Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death : Subgroup analyses from the warfarin-aspirin recurrent stroke study. In: Cerebrovascular Diseases. 2006 ; Vol. 22, No. 1. pp. 4-12.
@article{56cf052657c04ab4bbba64d021fdb695,
title = "Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: Subgroup analyses from the warfarin-aspirin recurrent stroke study",
abstract = "Background and Purpose: We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort. Methods: The WARSS compared the efficacy of adjusted-dose warfarin (INR 1.4-2.8) to aspirin (325 mg/day) for recurrent ischemic stroke or death within 2 years. The effect of warfarin and aspirin was compared among prespecified and exploratory subgroups with respect to sociodemographic and vascular risk factors, stroke subtype, arterial territory, and infarct topography. Hazard ratios and 95{\%} confidence intervals comparing warfarin to aspirin were calculated using Cox proportional hazards models. Differences in hazard ratios were tested using interaction terms. Results: No treatment differences between warfarin and aspirin were found across multiple prespecified subgroups. In a multivariate model, warfarin was associated with greater hazard among patients with moderate stroke severity (HR 1.63, 95{\%} CI 1.005-2.64, p = 0.047) and a greater benefit among those with posterior circulation location without brainstem infarction (HR 0.54, 95{\%} CI 0.33-0.88, p = 0.013). In post-hoc analyses of the cryptogenic subgroup, warfarin was associated with worse outcomes among patients with moderate stroke severity and better outcomes among those without baseline hypertension or with posterior circulation infarcts sparing the brainstem. Conclusions: In the WARSS, the majority of subgroup analyses showed no benefit of warfarin over aspirin. Warfarin benefit was limited to brainstem-sparing posterior circulation infarcts and select cryptogenic stroke subgroups. Pending future clinical trial evidence to the contrary, antiplatelets are recommended for survivors of noncardioembolic stroke.",
keywords = "Anticoagulants, Antiplatelet therapy, Cryptogenic stroke, Recurrent stroke",
author = "Sacco, {Ralph L} and Shyam Prabhakaran and Thompson, {J. L P} and Amy Murphy and Sciacca, {Robert R.} and Bruce Levin and Mohr, {J. P.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1159/000092331",
language = "English",
volume = "22",
pages = "4--12",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death

T2 - Subgroup analyses from the warfarin-aspirin recurrent stroke study

AU - Sacco, Ralph L

AU - Prabhakaran, Shyam

AU - Thompson, J. L P

AU - Murphy, Amy

AU - Sciacca, Robert R.

AU - Levin, Bruce

AU - Mohr, J. P.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Background and Purpose: We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort. Methods: The WARSS compared the efficacy of adjusted-dose warfarin (INR 1.4-2.8) to aspirin (325 mg/day) for recurrent ischemic stroke or death within 2 years. The effect of warfarin and aspirin was compared among prespecified and exploratory subgroups with respect to sociodemographic and vascular risk factors, stroke subtype, arterial territory, and infarct topography. Hazard ratios and 95% confidence intervals comparing warfarin to aspirin were calculated using Cox proportional hazards models. Differences in hazard ratios were tested using interaction terms. Results: No treatment differences between warfarin and aspirin were found across multiple prespecified subgroups. In a multivariate model, warfarin was associated with greater hazard among patients with moderate stroke severity (HR 1.63, 95% CI 1.005-2.64, p = 0.047) and a greater benefit among those with posterior circulation location without brainstem infarction (HR 0.54, 95% CI 0.33-0.88, p = 0.013). In post-hoc analyses of the cryptogenic subgroup, warfarin was associated with worse outcomes among patients with moderate stroke severity and better outcomes among those without baseline hypertension or with posterior circulation infarcts sparing the brainstem. Conclusions: In the WARSS, the majority of subgroup analyses showed no benefit of warfarin over aspirin. Warfarin benefit was limited to brainstem-sparing posterior circulation infarcts and select cryptogenic stroke subgroups. Pending future clinical trial evidence to the contrary, antiplatelets are recommended for survivors of noncardioembolic stroke.

AB - Background and Purpose: We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort. Methods: The WARSS compared the efficacy of adjusted-dose warfarin (INR 1.4-2.8) to aspirin (325 mg/day) for recurrent ischemic stroke or death within 2 years. The effect of warfarin and aspirin was compared among prespecified and exploratory subgroups with respect to sociodemographic and vascular risk factors, stroke subtype, arterial territory, and infarct topography. Hazard ratios and 95% confidence intervals comparing warfarin to aspirin were calculated using Cox proportional hazards models. Differences in hazard ratios were tested using interaction terms. Results: No treatment differences between warfarin and aspirin were found across multiple prespecified subgroups. In a multivariate model, warfarin was associated with greater hazard among patients with moderate stroke severity (HR 1.63, 95% CI 1.005-2.64, p = 0.047) and a greater benefit among those with posterior circulation location without brainstem infarction (HR 0.54, 95% CI 0.33-0.88, p = 0.013). In post-hoc analyses of the cryptogenic subgroup, warfarin was associated with worse outcomes among patients with moderate stroke severity and better outcomes among those without baseline hypertension or with posterior circulation infarcts sparing the brainstem. Conclusions: In the WARSS, the majority of subgroup analyses showed no benefit of warfarin over aspirin. Warfarin benefit was limited to brainstem-sparing posterior circulation infarcts and select cryptogenic stroke subgroups. Pending future clinical trial evidence to the contrary, antiplatelets are recommended for survivors of noncardioembolic stroke.

KW - Anticoagulants

KW - Antiplatelet therapy

KW - Cryptogenic stroke

KW - Recurrent stroke

UR - http://www.scopus.com/inward/record.url?scp=33745052164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745052164&partnerID=8YFLogxK

U2 - 10.1159/000092331

DO - 10.1159/000092331

M3 - Article

C2 - 16567931

AN - SCOPUS:33745052164

VL - 22

SP - 4

EP - 12

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 1

ER -